Plant-based vaccine against SARS-CoV-2 shows promise

NewsGuard 100/100 Score

Researchers at Canadian biotechnology company Medicago report that Phase 1 trials of a plant-based vaccine for SARS-CoV-2 are underway and showing promise.

The team, led by Dr. Brian Ward, professor of Medicine and Microbiology at McGill University, Canada, has published data from an initial clinical trial study in which 180 adults aged between 18 and 55 were injected with a plant-produced virus-like particle (VLP). The trial indicates that this novel VLP developed to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease, shows strong immunogenic properties and no serious adverse effects.

The research paper is available to read at Nature Medicine.

The SARS-CoV-2 virus is now responsible for over 165 million cases globally. Since the World Health Organization classified the disease as a pandemic almost 18 months ago, 180 vaccine candidates have been developed, 12 of which have been given authorization for vaccine use.

In this new study, Ward and colleagues describe their new plant-based vaccine candidate that has successfully navigated phase 1 human trials.

The vaccine is produced by inserting the SARS-CoV-2 protein into the nuclei of benthi plants (Nicotiana benthamiana, commonly found in Australia). This is then transfected into a bacterial cell (Agrobacterium tumefaciens) to use as a vector. These cells are then injected into the bloodstream, where they express the S protein to stimulate the immune system.

The research tested this compound in three different magnitudes (3.75 μg, 7.5 μg, and 15 μg), each either adjuvanted with CpG1018, AS03, or without an adjuvant. CpG 1018 and AS03 are compounds commonly added to vaccines to induce a more robust immune response by the body.

All participants received their second dosage 21 days after their first and were sampled again on day 42 (after initial injection). As expected, the addition of either CpG 1018 or AS03 adjuvants did aid and increase the immunogenic response exhibited by the body, particularly so with AS03.

Only mild adverse effects were observed in portions of the sample in all test groups, with roughly two-thirds of each group experiencing mild pain at the injection site after receiving the first dosage, and a fifth reported experiencing headaches or fatigue. In the subsequent second dose, this remained about the same, although reports of fatigue and headache increased to a third. However, all adverse effects were noted to be mild to moderate, with no serious effects taking place.

The aim of this study was to determine the best dosage and adjuvant combination to boost immunity. Based on their results, a two-dose schedule with a concentration of 3.75 μg in addition to ASO3 showed the best results, and these results have since advanced to phase 2/3 trials in Canada and the United States.

These results are promising, highlighting yet another diverse tool in our arsenal against the spread of the global COVID-19 pandemic.

Journal reference:
Michael Burgess

Written by

Michael Burgess

Michael graduated with a first-class degree in Zoology from the University of Hull, and later received a Masters degree in Palaeobiology from the University of Bristol.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Burgess, Michael. (2021, May 21). Plant-based vaccine against SARS-CoV-2 shows promise. News-Medical. Retrieved on April 15, 2024 from

  • MLA

    Burgess, Michael. "Plant-based vaccine against SARS-CoV-2 shows promise". News-Medical. 15 April 2024. <>.

  • Chicago

    Burgess, Michael. "Plant-based vaccine against SARS-CoV-2 shows promise". News-Medical. (accessed April 15, 2024).

  • Harvard

    Burgess, Michael. 2021. Plant-based vaccine against SARS-CoV-2 shows promise. News-Medical, viewed 15 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single dengue vaccine dose shows mixed results: Protection hinges on prior exposure